The in vivo activity of the Merck antifungal echinocandin drug candidate MK-0991 (L-743,872) was evaluated in mouse models of disseminated candidiasis, aspergillosis, and cryptococcosis. The echinocandins are potent inhibitors of 1,3-␤-D-glucan synthase. Two models of disseminated candidiasis were used. In a Candida albicans mouse survival model with both DBA/2N and CD-1 mice, estimates of the 50% effective doses (ED 50 s) of MK-0991 were 0.04 and 0.10 mg/kg of body weight/dose at 21 days after challenge, respectively. In a C. albicans target organ assay (TOA) with DBA/2N mice, MK-0991 at levels of >0.09 mg/kg/dose significantly reduced the numbers of C. albicans CFU/g of kidneys compared to the numbers in the kidneys of control mice from 1 to 28 days after challenge. Even when given as a single intraperitoneal dose either 30 min or 24 h after challenge, MK-0991 was effective and significantly reduced the numbers of C. albicans CFU/g of kidney compared to those in the controls. MK-0991 was >300-fold less active when it was administered orally than when it was administered parenterally. MK-0991 was efficacious in mouse TOAs against other C. albicans strains and Candida species including Candida tropicalis, Candida (Torulopsis) glabrata, Candida lusitaniae, Candida parapsilosis, and Candida krusei. MK-0991 was ineffective against disseminated Cryptococcus neoformans infections. In the model of disseminated aspergillosis in mice, MK-0991 at doses of >0.02 mg/kg/dose significantly prolonged the survival of DBA/2N mice, with estimates of the ED 50 and ED 90 of MK-0991 being 0.03 and 0.12 mg/kg/dose, respectively, at 28 days after challenge. MK-0991 is a potent, parenterally administered therapeutic agent against disseminated candidiasis and aspergillosis that warrants further investigation in human clinical trials.
a DBA/2N mice (10 mice/group) were infected i.v. with 1.8 ϫ 10 6 conidia/ mouse. Mice received their first treatment 30 min after challenge; for mice receiving delayed therapy, however, the first treatment was administered 24 h after challenge. All mice were treated for a total of 5 days. ED 50 s and ED 90 s were estimated at day 28 after challenge.
b Values in parentheses are 95% confidence intervals. c NE, confidence interval could not be estimated.
Sabouraud dextrose agar (SDA; BBL, Cockeysville, Md.) slants at 30°C for 4 to 5 days. Conidia were washed from the surfaces of several (three to four) agar slants and placed into sterile saline with 0.01% Tween 20 (Fisher Scientific, Fair Lawn, N.J.), and the concentration of conidia was quantitated by counting with a hemacytometer. The viable count was confirmed by serially diluting the conidial suspension 10-fold and plating the inoculum on SDA plates. Merck cultures of Candida species (listed in Table 5 ) were grown on SDA at 35°C for 24 h.
Cryptococcus neoformans MY2061 (a human isolate obtained from the University of Wisconsin, Madison) was grown on SDA at 35°C for 48 to 72 h. Yeast cells were washed from the surfaces of one to two SDA plates, and cell concentrations were quantitated by counting with a hemacytometer. The viable count was confirmed by serially diluting the yeast suspension 10-fold and plating each inoculum onto SDA plates. Survival studies. Disseminated aspergillosis was induced in DBA/2N mice by the method described previously (1) . Briefly, mice were infected by intravenous (i.v.) inoculation of 0.2 ml of the A. fumigatus MF5668 spore suspension (5.0 ϫ 10 5 to 2.0 ϫ 10 6 conidia/mouse) into the lateral tail vein. Therapy was initiated either within 30 min after challenge or, in the case of the delayed therapy, 24 h after challenge. The mice were treated for a total of 5 days. MK-0991 was administered intraperitoneally (i.p.) either once daily (q.d.) or twice-daily (b.i.d.). MK-0991 was also tested orally (p.o.) b.i.d. AmB was administered i.p. q.d.
Disseminated candidiasis was induced in DBA/2N and CD-1 mice by the i.v. inoculation of 0.2 ml of a Candida albicans MY1055 cell suspension into the lateral tail vein. Each DBA/2N mouse received 10 6 blastoconidia, and each CD-1 mouse received 10 7 blastoconidia. These inocula were previously determined to represent one 14-day 100% lethal dose for each strain of mouse. Therapy was initiated within 30 min after challenge, and the mice were treated for a total of 4 days. MK-0991 was administered either i.p. or p.o. b.i.d.
Disseminated cryptococcosis was induced in DBA/2N mice by the i.v. inoculation of 0.2 ml of a C. neoformans MY2061 cell suspension (2 ϫ 10 6 cells/mouse) into the lateral tail vein. Therapy was initiated within 30 min after challenge, and the mice were treated i.p. for a total of 4 days with MK-0991 (b.i.d.) or AmB (q.d.).
Compounds were tested at titrated concentrations (serial fourfold dilutions), with 10 mice per therapy group. Infected sham-treated mice were administered sterile water. Morbidity and mortality were recorded daily for 21 days in the candidiasis and cryptococcosis models and for 28 days in the aspergillosis model.
TOAs. DBA/2N mice were infected i.v. with approximately one 50% lethal dose of C. albicans MY1055 (7.5 ϫ 10 4 yeast cells per mouse). The inocula for the other Candida strains and Candida (Torulopsis) glabrata are listed in Table 5 . It should be noted, that strains of Candida lusitanae, Candida parapsilosis, Candida krusei, and Candida glabrata were not lethal for mice, and the inoculum used for each strain was previously shown to give detectable kidney colonization at day Therapy was initiated within 30 min after challenge, and mice were treated for a total of 4 days. Compounds were administered as described above. The TOA for Candida species monitors the numbers of CFU per gram of paired kidneys at time points following challenge (target organ kidney assay [TOKA] ). The TOA for C. neoformans monitors the numbers of CFU per gram of brain and spleen at time points following challenge (target organ brain and spleen assay). Organs from euthanized mice (five mice/group/experiment) were removed by aseptic technique, weighed, and placed in sterile Whirl Pak bags (Fisher Scientific) containing 5 ml of sterile saline. The organs were homogenized in the bags and serially diluted in saline, and aliquots were plated onto SDA. The plates were incubated at 35°C, and the organisms were enumerated after 48 h for Candida species and 72 h for Cryptococcus. The mean numbers of CFU per gram of tissue in the organs of the treated groups were compared with those in the organs of sham-treated mice. Percent clearance indicates the percentage of mice in which there was no detectable yeast; because of the dilution scheme, the limit of detection was 50 yeast cells per brain, spleen, or pair of kidneys.
Statistical analyses. Experiment-to-experiment variability was accounted for in all analyses for data that were pooled across experiments. In the disseminated aspergillosis model, the 50% effective doses (ED 50 s) and the ED 90 s were estimated by a robust probit method (29, 35) from survival rates calculated by the Kaplan-Meier (24) technique at days 21 and 28 after challenge. In the disseminated candidiasis model, ED 50 s were estimated at days 7, 14, and 21 after challenge by the method of Knudson and Curtis (25) and were defined as the concentration of compound in (milligrams per kilogram of body weight per dose) that protected 50% of mice from lethal challenge. In the target organ assays, inverse regression (16) was used to estimate the doses which reduced the CFU/ organ counts so that they were 90% lower than those for the sham-treated controls. The mean log 10 numbers of yeast CFU/organ for mice in the dose groups were compared to those sham-treated control mice by Fisher's leastsignificant-difference t-test procedure (18) . Comparisons were determined significant at the level of ␣ equal to 0.05. Efficacy in the TOA of disseminated candidiasis. MK-0991 administered as a single i.p. dose given either immediately after challenge or 24 h after challenge (delayed) was tested for efficacy in reducing recoverable yeast from the kidneys of mice challenged i.v. with C. albicans MY 1055. ED 90 s were estimated on day 7 after challenge and were based on the mean log 10 numbers of CFU per gram of paired kidneys from treated groups compared to those for paired kidneys from shamtreated controls. For comparison, AmB was also tested. The data are presented in Table 3 . The ED 90 of single-dose therapy with MK-0991 was 0.01 mg/kg, and the value for AmB was 0.04 mg/kg. The ability of MK-0991 to sterilize the kidneys of mice was superior to that of AmB. Even when therapy was delayed until 24 h after challenge, MK-0991 at doses of Ն0.02 mg/kg significantly reduced the load of C. albicans in the kidneys up to day 7 after challenge. As seen in the survival assay, MK-0991 had activity when it was administered p.o., but the ED 90 (4.40 mg/kg/dose) was considerably higher than that of parenterally administered drug (Table 4) . Even MK-0991 administered orally at 50 and 25 mg/kg showed high percentages of kidney sterilization (90 and 60%, respectively).
RESULTS

Efficacy
The efficacy of MK-0991 against several Candida species is shown in Table 5 . MK-0991 was highly effective against the four other C. albicans strains tested, with ED 90 s ranging from 0.003 to 0.02 mg/kg/dose. Against three C. tropicalis strains the ED 90 s ranged from 0.03 to 0.055 mg/kg/dose. The efficacy of MK-0991 against two C. glabrata strains and one strain each of C. lusitaniae, C. parapsilosis, and C. krusei was also tested. It should be noted that these organisms are not lethal for normal mice and very high inocula were required to establish acceptable kidney colonization. The ED 90 s for the C. glabrata strains were 0.03 and 0.06 mg/kg/dose, and for C. lusitaniae and C. parapsilosis the ED 90 s were 0.16 and 1.0 mg/kg/dose, respectively. An effective dose for the C. krusei strain could not be calculated due to the lack of a significant dose-response relationship over the range of doses tested in this assay. However, a significant reduction from the effective dose for the shamtreated control was found at a level of 0.375 mg/kg/dose.
The efficacy of MK-0991 against C. albicans MY 1055 over time, as determined by the TOKA, is indicated in Fig. 2 . MK-0991 at 0.09 and 0.375 mg/kg rapidly clears the kidneys of recoverable yeast, and the counts remained greater than 2 log 10 CFU/g of kidney lower than those for the sham-treated control group for 28 days after challenge.
Efficacy in the TOA for disseminated cryptococcosis. MK-0991 was tested for its activity both in protecting mice from lethal challenge and in reducing the numbers of yeast recoverable from both the brains and spleens (day 7 after challenge) of mice infected i.v. with C. neoformans. MK-0991 at concentrations up to 20 mg/kg/dose (i.p. b.i.d.) was ineffective at protecting mice from lethal challenge and reducing the counts in the organs. AmB fully protected mice from the lethal challenge and cleared 100% of the yeast from the organs when it was used at 0.31 mg/kg (data not shown).
DISCUSSION
MK-0991 has been reported to have in vitro activity against most of the clinically relevant species of Candida (6, 7, 17, 20, 39) and C. glabrata (6, 7, 17, 39) including AmB-and azoleresistant isolates (6, 7, 32, 40) . Studies of the growth inhibition kinetics of MK-0991 against C. albicans and C. tropicalis demonstrated that the drug has fungicidal activity, with a 99.9% reduction in growth by 5 to 7 h after administration (6, 7) . A good correlation between in vitro activity and efficacy has also been shown for MK-0991 in our models of disseminated candidiasis. Potent in vivo efficacy in other models of disseminated candidiasis in neutropenic mice (30, 38) and against a fluconazole-resistant Candida isolate (30) has been reported for MK-0991. MK-0991 has also been shown to have in vivo efficacy in a mouse model of oropharyngeal and gastrointestinal candidiasis (19) . MICs were determined by a broth microdilution method described by Bartizal et al. (6) . FCZ r , fluconazole resistant. c Mean log 10 CFU per gram at day 7 after challenge for paired kidneys. Percent sterilization indicates the percentage of mice with no detectable yeast; the limit of detection was 50 yeast cells per pair of kidneys. n, number of mice per group; ‫,ء‬ the mean was statistically significantly less than that for the sham-treated control at P Յ 0.05 according to Fisher's least-significant-difference t test. d ED 90 s were estimated by comparison of mean log 10 CFU per gram at day 7 after challenge for paired kidneys from the treated groups to the values for paired kidneys from sham-treated controls. Values in parentheses are 95% confidence intervals. e NT, not tested. f NE, effective doses were not estimated due to the lack of a significant dose-response relationship over the range of doses tested.
Although the pneumocandins do not give MICs for Aspergillus species when tested by the classic broth microdilution assays (8, 33) , this class of compounds has been shown to have profound morphological effects, in vitro; these are attributed to inhibition of 1,3-␤-D-glucan synthesis (26, 27) . These measurable morphological effects, termed the minimal effective concentration, appear to correlate well with the potent activity of L-733560 in animal models of A. fumigatus infection (1, 3, 10) . MK-0991 was highly effective in our model of disseminated aspergillosis in mice (2) and in another model of pulmonary aspergillosis in rats (9) .
It has been reported (17, 20) that MK-0991 has good in vitro activity against Histoplasma capsulatum, and it has also been reported that MK-0991 has in vivo efficacy against H. capsulatum in a murine model of histoplasmosis (31) . The reported in vitro activity of MK-0991 against other dimorphic fungi and the opportunistic molds showed considerable species and strain variability (13, 15, 17) .
Although MK-0991 exhibited measurable in vitro activity (MICs, 16 to 32 g/ml) against clinical isolates of C. neoformans (6, 7, 17, 20) , this activity did not yield efficacy in our in vivo models. However, recent in vitro studies indicate that MK-0991 may enhance the efficacies of fluconazole and AmB against C. neoformans (21).
MK-0991 administered both parenterally and p.o. has been shown to exhibit potent in vivo activity against P. carinii cysts in an immunocompromised rat model (34) . Other echinocandins have also been shown to have anti-Pneumocystis activity (5, 14, 36, 37) .
Comparative pharmacokinetics of MK-0991 in mice, rats, rhesus monkeys, and chimpanzees have shown that it has good bioavailability when it is administered parenterally (22, 23) . MK-0991 had half-lives in plasma of 5.2 and 7.6 h and a high level of distribution in tissue (22, 23) . MK-0991 has been shown to have a low bioavailability when it is administered p.o. (22) , which correlates with the greatly reduced efficacy when it was administered p.o. in our murine models. The potent activity of MK-0991 against clinically relevant fungal species combined with its good aqueous solubility, favorable bioavailability when administered parenterally, and acceptable therapeutic index has led Merck & Co. to initiate safety and clinical efficacy studies in humans.
